Key facts
- Isomorphic Labs’s last known valuation is $1.8B (Mar 2025).
- It has raised $579.1M; the latest was Early Stage VC ($579.1M) in Mar 2025.
- Notable investors include GV, Thrive Capital, Alphabet.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Isomorphic Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Isomorphic Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Isomorphic Labs
Operator of a digital biology company intended to redefine drug discovery with the power of artificial intelligence. The company reimagines the entire drug discovery process from first principles with an AI-first approach and ultimately to model and understand some fundamental mechanisms of life, enabling clients in the improvement of patients' health.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 338
- Website
- isomorphiclabs.com/
- Ownership
- Privately Held (backing)
Isomorphic Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Isomorphic Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Isomorphic Labs in its N-PORT filings yet. We sweep new filings monthly.